Management strategies depend on disease extent and severity
DUAL GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON-LIKE PEPTIDE-1 RECEPTOR CO-AGONISTS In 2015, following the success of dual GIP/GLP-1 receptor co-agonists, the first triple GLP-1/GIP/glucagon receptor triagonist was developed with the rationale that the synergistic effect of the three gastrointestinal hormones will achieve further efficacy compared to the dual gastrointestinal hormone approach [58]
The most common side effects reported in clinical trials include mild to moderate nausea, vomiting, constipation, and reduced appetite
American Journal of Physiology-Endocrinology and Metabolism , 291 (6), E1290-E1294
The review also frames GLP-1RA use against the backdrop of rising obesity rates, substantial health care costs, and the high overlap between obesity and diagnosed diabetes
Adjunctive Therapy with Pramlintide Lowers HbA1c without Concomitant Weight Gain and Increased Risk of Severe Hypoglycemia in Patients with Type 1 Diabetes Approaching Glycemic Targets
